linjc16/ctgov huggingface dataset:
Markers of Atrial Cardiopathay

Study Overview
=================
Brief Summary
-----------------
Marker of atrial cardiopathay as apredictor value of ischemic stroke

Detailed Description
-----------------
detection of the presence of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with a one-year follow-up for any cardioembolic events (stroke /TIA).

Official Title
-----------------
Markers of Atrial Cardiopathay

Conditions
-----------------
Atrial Cardiopathy

Intervention / Treatment
-----------------
* Diagnostic Test: Holter ,Echo , Speckle tracking echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients complaining of palpitation referred for Holter monitoring Exclusion Criteria: • Valvular AF, moderate to severe mitral/ tricuspid/ aortic stenosis or regurgitation. Recent myocardial infarction within 3 months. Acute pulmonary embolism. Newly onset AF during or shortly after cardiac surgery. Specific type of cardiomyopathy such as cardiac amyloidosis, obstructive hypertrophic cardiomyopathy. Decompensation stage of organ failure

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Holter ,Echo , Speckle tracking echocardiography|A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of any underlying arrythmia after holter monitoring for twenty four hours | Detection of any underlying arrythmia after holter monitoring for twenty four hours | Detection of any underlying arrythmia after holter monitoring for twenty four hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA). | Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA). | Detection of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with 6 month follow-up for any cardioembolic events (stroke /TIA). |
Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids

Study Overview
=================
Brief Summary
-----------------
This is a retrospective, case-control study of 75 patients having undergone a robotic-assisted laparoscopic myomectomy were compared to patients having undergone myomectomy via laparotomy. Both groups had 3 or fewer fibroids confirmed by pre-operative MRI or on final pathology report. Charts were reviewed for surgical and post-operative variables

Official Title
-----------------
Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids

Conditions
-----------------
Fibroid Uterus

Intervention / Treatment
-----------------
* Procedure: Robot-assisted Laparoscopic myomectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: uterus less than or equal to 20 weeks in size by office exam and no greater than three intramural fibroids on pre-operative MRI. Exclusion Criteria: significant medical problems limiting their ability to undergo a prolonged laparoscopic procedure and could not have had previous uterine surgery.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Robot Assisted Laparoscopic Myomectomy<br> | Procedure: Robot-assisted Laparoscopic myomectomy<br>* Robot-assisted Laparoscopic myomectomy<br>|
| Myomectomy via Laparotomy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative variables, including estimated blood loss, length of stay, days to a regular diet and febrile morbidity |  | 1 day |
Clinical Study of the Topcon Pachymeter TRK-3 to Evaluate Agreement and Precision

Study Overview
=================
Brief Summary
-----------------
Agreement and Precision of corneal thickness measurement (pachymetry) function of the test device TRK-3 and the predicate device SP-1P will be evaluated in volunteers, and safety will be evaluated.

Official Title
-----------------
Clinical Study of the Topcon Pachymeter TRK-3 to Evaluate Agreement and Precision

Conditions
-----------------
Corneal Thickness

Intervention / Treatment
-----------------
* Device: SP-1P


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals who gave written informed consent to participate in the clinical trial by their free will. Individuals who aged 20 years or older at the time of informed consent Individuals who were deemed eligible for the study by the investigator for screening prior to enrollment. Subjects who are able to comply with compliance items during participation in the clinical trial, undergo medical examination and examination specified in the protocol, and report subjective symptoms, etc. Exclusion Criteria: Individuals with ocular diseases that may affect corneal thickness measurement (blindness, corneal perforation, bullous keratopathy, nystagmus, etc.) or who have a history of ocular diseases and are considered by the investigator to be ineligible for participation in the study. Individuals who have or are suspected of suffering from ocular or systemic infections. Other persons who are judged by the investigator to be unfavorable candidates for the study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults 20 years old or older<br> | Device: SP-1P<br>* A subject undergoes corneal thickness measurement with pachymeter.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal thickness | Corneal thickness | 1 day |
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the behavioral and physiological effects of buprenorphine and naloxone, both alone and in combination.

Official Title
-----------------
Effects of Buprenophine and Naloxone in Opiate Addicts

Conditions
-----------------
Opioid-Related Disorders, Substance-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opiate dependence
Inter Scorers Agreement for OSA Screening Scores.

Study Overview
=================
Brief Summary
-----------------
Four scores are usually performed to detect OSA (Obstructive Sleep Apnea) patients. These four scores are: STOP-Bang, P-SAP, OSA50 and DES-OSA. These scores have been previously validated. However, a comparison between scorers in the realization of these scores has never been performed.

Detailed Description
-----------------
Four scores are usually performed to detect OSA (Obstructive Sleep Apnea) patients. These four scores are: STOP-Bang, P-SAP, OSA50 and DES-OSA. These scores have been previously validated. However, a comparison between scorers in the realization of these scores has never been performed. The aim of this study was to evaluate this agreement using statistical methods.

Official Title
-----------------
Inter Scorers Agreement for OSA Screening Scores.

Conditions
-----------------
Sleep Apnea, Obstructive

Intervention / Treatment
-----------------
* Other: OSA scoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All preoperative patients in the Cabinet Medical ASTES Exclusion Criteria: Patient's refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Main Group - OSA Scoring<br>All patients include in this study for whom the four OSA scoring will be evaluated | Other: OSA scoring<br>* OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OSA Scoring | Should the inter-scorers agreement between OSA scoring be accurate? | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep Apnea, Obstructive, Mass Screening
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.

Detailed Description
-----------------
The duration of treatment is 10 weeks.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.

Conditions
-----------------
Hypercholesterolemia, Coronary Disease

Intervention / Treatment
-----------------
* Drug: MK0653, ezetimibe
* Drug: Comparator: ezetimibe, placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with elevated cholesterol and coronary heart disease Exclusion Criteria: Patients who do not meet specific cholesterol levels as required by the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0653, ezetimibe|nan|
|Drug: Comparator: ezetimibe, placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients reaching LDL goal of <2.60 mmol/L after 6 weeks of treatment |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elevated Cholesterol
Optimization of 99mTc-Sestamibi Activities in SPECT/CT Myocardial Perfusion Imaging

Study Overview
=================
Brief Summary
-----------------
This work suggests a methodology to adapt the injected radionuclide activity to the level of attenuation of each patient. The investigators propose a dose reduction adapted to the patient's weight, with no significant degradation of the image quality, in order to improve patients and staff radioprotection, standardize the image quality for easier clinical interpretation, and lead to radiopharmaceutical saving in the context of myocardial perfusion Imaging.

Official Title
-----------------
Personalization of 99mTc-Sestamibi Activities in SPECT/CT Myocardial Perfusion Imaging With the Cardiofocal SmartZoom® Collimator

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient underwent stress-test 99 mTc-Sestamibi SPECT/CT myocardial perfusion Imaging on a Siemens Intevo Bold Anger camera with the cardiofocal SmartZoom® collimator Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of counts | Number of counts in the myocardial region of interest | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical evaluation | Medical evaluation of image quality, in order to establish a correlation between the myocardial signal level and the clinical image quality | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myocardial SPECT, Sestamibi, SmartZoom, Cardiofocal collimator, Dose optimization
Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.

Study Overview
=================
Brief Summary
-----------------
All patients included in this search will be on anonymized file: Symptomatic patients consulting for suspicion of COVID 19 with indication to a screening (RT-PCR, Scanner) according to the criteria of the Ministry of Health. To evaluate the diagnostic performance of chest CT in screening for COVID-related lung injury in patients with a clinical suspicion of COVID. CT scan results for COVID according to French thoracic imaging society will be dichotomized into evocative or compatible (considered positive) non-evocative (considered negative) The results will be compared to the gold standard corresponding to a multiparametric element: the discharge summary. Ct Scan performance will be recorded and analyzed.

Official Title
-----------------
Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening. Comparison to Virological Testing and Multiparametric Gold Standard

Conditions
-----------------
The Gold Standard for Current SARS CoV2 Detection is RT-PCR

Intervention / Treatment
-----------------
* Diagnostic Test: Thoracic CT Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients suspected of COVID 19 consulting for diagnostic Exclusion Criteria: Delay between RT-PCR and Thoracic Scan greater than 6 days.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suspicion of COVID 19<br> | Diagnostic Test: Thoracic CT Scan<br>* Retrospective analysis of the thoracic CT scan results compared to final discharge summary<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID. | CT Report will dichotomized into evocative or non-evocative for COVID-related lung injury. | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening). | Initial virological RT-PCR results: positive or negative depending on the laboratories of the institutions. Scanner results according to French Thoracic Imaging Society. | 1 month |
Weight Fluctuation After Breast Cancer Treatment

Study Overview
=================
Brief Summary
-----------------
This study aims to identify and quantify the factors associated with excess weight gain following treatment for breast cancer. It is believed that breast cancer patients gain more than 4% of their weight at diagnosis which is likely accompanied by an increase in body fat and waist circumference. It is further thought that this excess weight and increase in body fat and waist circumference are associated to tumour characteristics, chemotherapy, menopause status at diagnosis and the presence of genes related to obesity. It is also thought that women treated with chemotherapy have higher levels of glucose and insulin.

Official Title
-----------------
Weight Fluctuation After Breast Cancer Treatment

Conditions
-----------------
Breast Cancer, Weight Gain

Intervention / Treatment
-----------------
* Procedure: Fasting blood sample.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females 18 years of age or older. Diagnosed with breast cancer between 1/1/2003 and 31/12/2007. Able to understand and willing to sign informed consent. Exclusion Criteria: Known diagnosis of previous breast/other cancer (other than completely resected non-melanoma skin cancer or successfully treated in situ cancer of the cervix. Known diagnosis of inflammatory bowel disease or malabsorption syndrome. Known diagnosis of endocrine problems associated with the development of obesity (cushings syndrome, hypo/hyperthyroid, thyroiditis) Treatment for psychiatric disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast cancer<br>Diagnosed with breast cancer 1/1/2003 - 31/12/2007. | Procedure: Fasting blood sample.<br>* Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To provide evidence of the relationship between weight gain following diagnosis of breast cancer and tumour characteristics, chemotherapy, menopause status at diagnosis and the presence of genes related to obesity. |  | 12-18 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Weight, Breast, Cancer
Secondhand Smoking in Asthmatic Children

Study Overview
=================
Brief Summary
-----------------
This study will investigate the interaction between GSTP1 / TNFa polymorphisms and passive smoking in children with asthma/wheezing. Contemporary second hand-smoke exposure will be confirmed by laboratory testing.

Official Title
-----------------
Association Between Maternal Smoking and GSTP1 and TNFa Polymorphism in Children With Asthma/Wheezing

Conditions
-----------------
Asthma in Children, Wheezing

Intervention / Treatment
-----------------
* Diagnostic Test: Lung function
* Diagnostic Test: White blood cell DNA extraction
* Diagnostic Test: Urinary testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 1-18 years old with doctor diagnosed asthma/wheezing Exclusion Criteria: Premature birth (< 36 gestation weeks) Asthma-like symptoms due to other conditions (infectious, congenital, mechanical)

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases<br>Children with asthma/wheezing whose mothers were active smokers during pregnancy | Diagnostic Test: Lung function<br>* Spirometry test<br>Diagnostic Test: White blood cell DNA extraction<br>* GSTP1 and TNFa polymorphisms with PCR<br>Diagnostic Test: Urinary testing<br>* Urinary nicotine and cotinine detection<br>|
| Controls<br>Children without asthma/wheezing whose mothers were active smokers during pregnancy | Diagnostic Test: Lung function<br>* Spirometry test<br>Diagnostic Test: White blood cell DNA extraction<br>* GSTP1 and TNFa polymorphisms with PCR<br>Diagnostic Test: Urinary testing<br>* Urinary nicotine and cotinine detection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GSTP1 and TNFa variants in children with asthma |  | 0 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Wheezing, GSTP1, TNFa, Secondhand smoking, Passive smoking, Intrauterine smoking